Search
Collplant Biotechnologies Ltd
CLGNAdd to Watchlist
0.440USD
+0.020+4.79%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
5.63MMarket Cap
LossP/E TTM
More Details of Collplant Biotechnologies Ltd Company
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Collplant Biotechnologies Ltd Info
Ticker SymbolCLGN
Company nameCollplant Biotechnologies Ltd
IPO dateSep 01, 1993
CEORotem (Eran)
Number of employees57
Security typeOrdinary Share
Fiscal year-endSep 01
Address4 Oppenheimer Street
CityREHOVOT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7670104
Phone972732325600
Websitehttps://www.collplant.com
Ticker SymbolCLGN
IPO dateSep 01, 1993
CEORotem (Eran)
Company Executives of Collplant Biotechnologies Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
56.14K
+44.53%
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
26.25K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
15.13K
+86.78%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
3.13K
--
Mr. Joseph Zarzewsky
Mr. Joseph Zarzewsky
Independent Director
Independent Director
3.13K
--
Ms. Alisa Lask
Ms. Alisa Lask
Independent Director
Independent Director
3.13K
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Founder, Chief Scientist
Founder, Chief Scientist
--
--
Dr. Nadav Orr
Dr. Nadav Orr
Vice President - Research & Development
Vice President - Research & Development
--
--
Dr. Ilana Belzer, Ph.D.
Dr. Ilana Belzer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Gili Hart
Dr. Gili Hart
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Yehiel Tal
Mr. Yehiel Tal
Chief Executive Officer
Chief Executive Officer
56.14K
+44.53%
Mr. Eran Rotem, CPA
Mr. Eran Rotem, CPA
Deputy Chief Executive Officer, Chief Financial Officer
Deputy Chief Executive Officer, Chief Financial Officer
26.25K
--
Dr. Philippe David Bensimon
Dr. Philippe David Bensimon
Vice President - Regulatory Affairs and Quality Assurance
Vice President - Regulatory Affairs and Quality Assurance
15.13K
+86.78%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
3.13K
--
Mr. Joseph Zarzewsky
Mr. Joseph Zarzewsky
Independent Director
Independent Director
3.13K
--
Ms. Alisa Lask
Ms. Alisa Lask
Independent Director
Independent Director
3.13K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2023Q2
FY2022
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Revenues from licensing agreement
2.00M
84.35%
Revenues from the sales of goods
371.00K
15.65%
By RegionUSD
Name
Revenue
Proportion
United States
2.18M
91.78%
Europe
98.00K
4.13%
Canada
96.00K
4.05%
Israel
1.00K
0.04%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Revenues from licensing agreement
2.00M
84.35%
Revenues from the sales of goods
371.00K
15.65%
Shareholding Stats
Updated: Sat, May 9
Updated: Sat, May 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sagy (Ami)
11.36%
Loewenbaum (George Walter II)
8.71%
St. Denis J. Villere & Company, LLC
4.21%
Pinnacle Associates Ltd.
3.82%
Loewenbaum (Lilian Shaw)
2.82%
Other
69.08%
Shareholders
Shareholders
Proportion
Sagy (Ami)
11.36%
Loewenbaum (George Walter II)
8.71%
St. Denis J. Villere & Company, LLC
4.21%
Pinnacle Associates Ltd.
3.82%
Loewenbaum (Lilian Shaw)
2.82%
Other
69.08%
Shareholder Types
Shareholders
Proportion
Individual Investor
26.88%
Investment Advisor/Hedge Fund
4.72%
Investment Advisor
4.47%
Hedge Fund
1.51%
Research Firm
0.13%
Family Office
0.12%
Venture Capital
0.10%
Bank and Trust
0.01%
Other
62.05%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
35
1.89M
13.14%
-218.89K
2025Q4
34
1.82M
18.05%
--
2025Q3
36
1.82M
18.09%
-351.44K
2025Q2
36
2.17M
13.51%
+569.42K
2025Q1
36
2.09M
19.82%
-180.41K
2024Q4
38
2.54M
24.36%
-57.22K
2024Q3
40
2.59M
23.16%
+143.75K
2024Q2
40
2.45M
24.33%
+72.69K
2024Q1
40
2.38M
24.25%
-401.71K
2023Q4
45
2.39M
26.23%
-101.34K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sagy (Ami)
1.64M
11.36%
-306.10K
-15.75%
Nov 19, 2025
Loewenbaum (George Walter II)
1.26M
8.71%
--
--
Nov 06, 2025
St. Denis J. Villere & Company, LLC
607.30K
4.21%
+18.58K
+3.16%
Dec 31, 2025
Pinnacle Associates Ltd.
557.19K
3.87%
+50.00K
+9.86%
Dec 31, 2025
Loewenbaum (Lilian Shaw)
406.29K
2.82%
-245.19K
-37.64%
Nov 06, 2025
Evans (Hugh M)
377.43K
2.62%
-1.00
-0.00%
Mar 15, 2025
AMH Equity, Ltd.
200.00K
1.39%
+39.15K
+24.34%
Sep 30, 2025
Brown Advisory
118.73K
0.82%
--
--
Dec 31, 2025
Pathstone
17.00K
0.12%
--
--
Dec 31, 2025
Tal (Yehiel)
31.14K
0.22%
--
--
Mar 15, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
